Physician profile
Jay Applebaum
NPI 1740214618
$12,897.49
in general payments reported to CMS, 2019-2025
33 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 78% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,379 · 2020: $1,341 · 2021: $1,937 · 2022: $2,140 · 2023: $1,635 · 2024: $2,313 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,931 · Education: $158 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,930.69 |
| Education | $157.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,961.74 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,238.47 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,207.93 | 2019-2025 | |
| Leo Pharma INC. | $1,016.74 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $976.72 | 2019-2025 | |
| Lilly USA, LLC | $887.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $863.12 | 2019-2024 | Dupixent |
| Pfizer INC. | $843.89 | 2019-2025 | |
| Galderma Laboratories, L.P. | $575.08 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Amgen INC. | $423.75 | 2020-2024 | Otezla |
| Ucb, INC. | $408.78 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $383.14 | 2019-2025 | Ilumya |
| Incyte Corporation | $336.45 | 2021-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $248.53 | 2020-2021 | |
| Dermavant Sciences, INC. | $213.73 | 2023-2024 | Vtama |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $199.26 | 2023-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.53 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.59 | 2019-2025 | Jublia, Siliq, Cabtreo |
| Strata Skin Sciences, INC. | $136.63 | 2020-2023 | Xtrac |
| Epi Health, LLC | $125.65 | 2021-2022 | |
| Biofrontera INC. | $107.54 | 2020-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Vyne Pharmaceuticals INC. | $55.57 | 2020-2021 | |
| Journey Medical Corporation | $55.40 | 2023-2025 | |
| Allergan, INC. | $50.22 | 2022 | |
| Dermira, INC. | $44.11 | 2020-2021 | |
| Sandoz INC. | $39.82 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $37.30 | 2024 | Ycanth |
| Almirall LLC | $36.72 | 2022-2025 | Klisyri |
| Organon LLC | $36.64 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $36.44 | 2021 | |
| Celgene Corporation | $23.63 | 2019 | |
| Mindera Corp | $14.58 | 2025 | |
| Prugen, INC. Pharmaceuticals | $12.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Applebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.